{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:45:57Z","timestamp":1755035157321,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Breast cancer (BC) is one of the most prevalent cancers in developing and developed countries among women worldwide. Mammography is one of the superior methods for BC detection, but it carries up to 20% false-negative results, especially in early cases. Histological examination of tissue biopsies and fine-needle aspiration cytology are invasive techniques. Hence, minimally invasive markers are needed for the improved detection of BC. microRNAs, small, noncoding, single-stranded RNAs functioning as tumor suppressor genes or oncogenes, are attractive biomarkers for early detection. This study aimed to examine the serum levels of miR21 and miR10b in patients with BC especially in the early stages compared to healthy controls to evaluate their potential use as BC biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included 90 females who were divided into two groups. Group I included 70 patients with BC and was subdivided into group Ia with 40 nonmetastatic BC patients and group Ib with 30 metastatic BC patients. Group II included 20 apparently healthy females as a control group. Serum miR21 and miR10b as biomarkers and <jats:italic>miR16<\/jats:italic> as a housekeeping gene were evaluated using real-time polymerase chain reaction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median levels of miR10b and miR21 were statistically significantly upregulated in the sera of patients with BC compared to healthy controls (<jats:italic>P<\/jats:italic> = 0.001). Receiver operating characteristic curve analyses demonstrated that serum levels of miR10b and miR21 were useful biomarkers for distinguishing between patients with BC and the control group, with an area under the curve (AUC) of 0.991 with 97.1% sensitivity and 100% specificity at a cutoff of 3.1 for miR10b and an AUC of 0.965 with 95.7% sensitivity and 85% specificity at a cutoff of 1.7 for miR21. Regarding the early stages of BC, the median levels of the fold change of serum miR21 and miR10b were statistically significantly higher in patients with BC (stages I and IIa) than in the control group (<jats:italic>P<\/jats:italic> &lt; 0.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Both miR21 and miR10b have valuable diagnostic roles in detecting the early stages of BC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-022-00115-6","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:02:22Z","timestamp":1649635342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["MicroRNA 21 and microRNA 10b: early diagnostic biomarkers of breast cancer in Egyptian females"],"prefix":"10.1186","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-8456","authenticated-orcid":false,"given":"Mai","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"El Gayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Normeen","family":"Hany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel Hamid","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reham","family":"Zeyada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"115_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics. Cancer J Clin. 2013;63:11. https:\/\/doi.org\/10.3322\/caac.21166.","journal-title":"Cancer J Clin"},{"key":"115_CR2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.3322\/caac.21203","volume":"136","author":"J Ferlay","year":"2014","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359\u201386. https:\/\/doi.org\/10.3322\/caac.21203.","journal-title":"Int J Cancer"},{"key":"115_CR3","doi-asserted-by":"publisher","unstructured":"Allam MF, Abd Elaziz KM. Evaluation of the level of knowledge of Egyptian women of breast cancer and its risk factors.\u00a0J Prev Med Hyg.\u00a02012;53:195\u20138. https:\/\/doi.org\/10.15167\/2421-4248\/jpmh2012.53.4.347.","DOI":"10.15167\/2421-4248\/jpmh2012.53.4.347"},{"key":"115_CR4","doi-asserted-by":"publisher","unstructured":"Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;437971. https:\/\/doi.org\/10.1155\/2014\/437971.","DOI":"10.1155\/2014\/437971"},{"key":"115_CR5","doi-asserted-by":"publisher","first-page":"djv048","DOI":"10.1093\/jnci\/djv048","volume":"107","author":"BA Kohler","year":"2015","unstructured":"Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual report to the nation on the status of cancer, 1975\u20132011, featuring incidence of breast cancer subtypes by race\/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048.","journal-title":"J Natl Cancer Inst"},{"key":"115_CR6","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up on behalf of the ESMO Guidelines. Ann Oncol. 2015;26:v8\u201330.","journal-title":"Ann Oncol"},{"key":"115_CR7","doi-asserted-by":"publisher","first-page":"738","DOI":"10.7326\/0003-4819-151-10-200911170-00010","volume":"151","author":"JS Mandelblatt","year":"2009","unstructured":"Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151:738\u201347.","journal-title":"Ann Intern Med"},{"key":"115_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/1742-6413.189637","volume":"13","author":"S Mitra","year":"2016","unstructured":"Mitra S, Dey P. Fine-needle aspiration and core biopsy in the diagnosis of breast lesions. Cytojournal. 2016;13:18.","journal-title":"Cytojournal"},{"key":"115_CR9","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/ijms16022810","volume":"16","author":"A Ren","year":"2015","unstructured":"Ren A, Dong Y, Tsoi H, Yu J. Detection of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol Sci. 2015;16:2810\u201323.","journal-title":"Int J Mol Sci"},{"key":"115_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/bcr2720","volume":"12","author":"L Ma","year":"2010","unstructured":"Ma L. Role of miR-10b in breast cancer metastasis. Breast Cancer Res. 2010;12:210.","journal-title":"Breast Cancer Res"},{"key":"115_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.lungcan.2017.10.002","volume-title":"Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Li T, Chen G. Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p; 2017. p. 6\u201311. https:\/\/doi.org\/10.1016\/j.lungcan.2017.10.002."},{"key":"115_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrc3932","volume":"15","author":"S Lin","year":"2015","unstructured":"Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321\u201333.","journal-title":"Nat Rev Cancer"},{"key":"115_CR13","doi-asserted-by":"publisher","unstructured":"Cha W, Fan R, Miao Y, Zhou Y. MicroRNAs as novel endogenous targets for regulation and therapeutic treatments.\u00a0Med Chem Commun.\u00a02018;9:396\u2013408. https:\/\/doi.org\/10.1039\/C7MD00285H.","DOI":"10.1039\/C7MD00285H"},{"key":"115_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn725","volume":"36","author":"P Mestdagh","year":"2008","unstructured":"Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F, et al. High-throughput stem-loop RT-PCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res. 2008;36:e143.","journal-title":"Nucleic Acids Res"},{"key":"115_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta C(T)) Method. Methods. 2001;25:402\u20138.","journal-title":"Methods."},{"key":"115_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000348678","volume":"36","author":"A Ozg\u00fcn","year":"2013","unstructured":"Ozg\u00fcn A, Karagoz B, Bilgi O, Tuncel T, Baloglu H, Kandemir EG. MicroRNA-21 as an indicator of aggressive phenotype in breast cancer. Onkologie. 2013;36:115\u20138. https:\/\/doi.org\/10.1159\/000348678.","journal-title":"Onkologie."},{"key":"115_CR17","first-page":"743","volume":"25","author":"J Gao","year":"2013","unstructured":"Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res. 2013;25:743\u20138.","journal-title":"Chin J Cancer Res"},{"key":"115_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40291-015-0143-6","volume":"19","author":"EA Toraih","year":"2015","unstructured":"Toraih EA, Mohammed EA, Farrag S, Ramsis N, Hosny S. Pilot study of serum microRNA-21 as a diagnostic and prognostic biomarker in Egyptian breast cancer patients. Mol Diagn Ther. 2015;19:179\u201390.","journal-title":"Mol Diagn Ther"},{"key":"115_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.gene.2016.01.042","volume":"590","author":"TM Motawi","year":"2016","unstructured":"Motawi TM, Sadik NA, Shaker OG, El Masry MR, Mohareb F. Study of microRNAs-21\/221 as potential breast cancer biomarkers in Egyptian women. Gene. 2016;590:210\u20139.","journal-title":"Gene."},{"key":"115_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2214\/AJR.15.15987","volume":"208","author":"P Grabler","year":"2017","unstructured":"Grabler P, Sighoko D, Wang L, Allgood K, Ansell D. Recall and cancer detection rates for screening mammography finding the sweet spot. AJR Am J Roentgenol. 2017;208:208\u201313.","journal-title":"AJR Am J Roentgenol"},{"key":"115_CR21","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.3747\/co.25.3770","volume":"25","author":"JM Seely","year":"2018","unstructured":"Seely JM, Alhassan T. Screening for breast cancer in what should we be doing today? Curr Oncol. 2018;25:S115\u201324.","journal-title":"Curr Oncol"},{"key":"115_CR22","doi-asserted-by":"publisher","unstructured":"Petrovi\u0107 N, Mandu\u0161i\u0107 V, Stanojevi\u0107 B, Luki\u0107 S. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion.\u00a0Med Oncol.\u00a02014;31(3):867. https:\/\/doi.org\/10.1007\/s12032-014-0867-x.","DOI":"10.1007\/s12032-014-0867-x"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-022-00115-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-022-00115-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-022-00115-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:04:16Z","timestamp":1649635456000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-022-00115-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["115"],"URL":"https:\/\/doi.org\/10.1186\/s43046-022-00115-6","relation":{},"ISSN":["2589-0409"],"issn-type":[{"type":"electronic","value":"2589-0409"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local ethics committee of the Clinical and Chemical Pathology Department, Faculty of Medicine Cairo University (2017). Informed consent was obtained from the participants before the commencement of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}